Pharma BD Deal Intelligence
A $130M all-cash Merck acquisition of Insmed's follow-on biologics pipeline and Boulder manufacturing facility that never yielded an approved product. Merck liquidated the site to KBI Biopharma just five years later as part of a $2.5B cost-cutting restructuring—a clean bust.
Merck's $130M bet on a follow-on biologics/manufacturing platform produced no approved product and was liquidated five years later as part of a cost-cutting restructuring.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FierceBiotech framed the deal as a clear positive for both sides — Merck advanced its newly created BioVentures FOB unit, and Insmed locked in non-dilutive…
Drug Discovery News positioned the transaction as Merck's strategic biosimilars commitment, with $130M securing manufacturing capacity and a pipeline that…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Insmed sold its follow-on biologics (FOB) platform — including the Phase 3 rG-CSF candidate INS-19, the Phase 1 pegylated rG-CSF INS-20, and a Boulder, Colorado biologics manufacturing facility — to Merck for $130 million in gross proceeds, with no further milestone or royalty obligations. The transaction advanced Merck's newly formed BioVentures biosimilars unit while giving Insmed non-dilutive cash to focus on its Iplex program. Announced February 2009.
Merck's $130M bet on a follow-on biologics/manufacturing platform produced no approved product and was liquidated five years later as part of a cost-cutting restructuring.
Assessment window: 15yr post-close.
$130M Gross deal value (asset sale)
Chemotherapy-induced neutropenia is a common and dangerous side effect of cytotoxic cancer therapy in which patients lose infection-fighting white blood cells, raising hospitalization and mortality risk. Granulocyte colony-stimulating factor (G-CSF) — branded Neupogen (filgrastim) and Neulasta (pegfilgrastim) by Amgen — is given prophylactically or therapeutically to restore neutrophil counts and reduce febrile neutropenia.
In 2009, Amgen's Neupogen and Neulasta franchise generated multi-billion-dollar annual revenue and faced impending biosimilar competition once US and EU regulatory pathways matured. Sandoz (Zarzio/Zarxio) and Teva (Granix/tbo-filgrastim) led the European biosimilar wave; Apotex, Hospira, and Coherus were also building programs. Insmed's INS-19 (recombinant G-CSF, Phase 3) and INS-20 (pegylated rG-CSF, Phase 1) targeted exactly this filgrastim/pegfilgrastim opportunity, packaged with a 50,000-sq-ft Boulder, CO biologics manufacturing facility. Merck — newly committed to follow-on biologics through its Merck BioVentures unit announced in December 2008 — paid $130M gross to bolt on a clinical-stage program plus the manufacturing footprint, leapfrogging years of internal capability build. The deal was strategically pivotal because the US BPCIA biosimilar pathway was still being legislated (eventually enacted in March 2010), and Merck signaled it intended to be a tier-one biosimilar player. Ultimately Merck wound down the BioVentures effort by 2014 and exited several FOB programs, but at deal time analyst sentiment was unambiguously bullish on the strategic logic. Source: https://www.fiercebiotech.com/biotech/merck-co-inc-mrk-to-pay-130-million-to-insmed-incorporated-insm-biologics-deal
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Insmed Inc. (Follow-on Biologics platform) (this deal) | 2009 | $130M | 16 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2009 deals · Merck & Co. Inc. deals